YM543

CAS No. 1174340-24-9

YM543( YM-543 | YM 543 )

Catalog No. M10592 CAS No. 1174340-24-9

A potent, selective and orally active SGLT2 inhibitor with IC50 of 8.9 nM, 280-fold selectivity over SGLT1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    YM543
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective and orally active SGLT2 inhibitor with IC50 of 8.9 nM, 280-fold selectivity over SGLT1.
  • Description
    A potent, selective and orally active SGLT2 inhibitor with IC50 of 8.9 nM, 280-fold selectivity over SGLT1; dose-dependently and significantly reduces blood glucose levels and improves glucose tolerance with a concomitant increase in urinary glucose excretion, also significantly reduces hyperglycemia in type 2 diabetic mice.Diabetes Phase 2 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    YM-543 | YM 543
  • Pathway
    GPCR/G Protein
  • Target
    SGLT
  • Recptor
    SGLT
  • Research Area
    Metabolic Disease
  • Indication
    Diabetes

Chemical Information

  • CAS Number
    1174340-24-9
  • Formula Weight
    500.611
  • Molecular Formula
    C28H38NO7+
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (2S,3R,4R,5S,6R)-2-(5-(azulen-2-ylmethyl)-2-hydroxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, 2-hydroxy-N,N,N-trimethylethan-1-aminium salt

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yokono M, et al. Endocr Res. 2013 Feb 1. 2. Ikegai K, et al. Bioorg Med Chem. 2013 Jul 1;21(13):3934-48. 3. Nakada N. Pharm Res. 2017 Apr;34(4):874-886.
molnova catalog
related products
  • SHR3824

    SHR3824 is a potent, selective SGLT2 inhibitor with IC50 of 2.38 nM.

  • YM543

    A potent, selective and orally active SGLT2 inhibitor with IC50 of 8.9 nM, 280-fold selectivity over SGLT1.

  • Licogliflozin

    A novel sodium glucose transporter type 1 and type 2 (SGLT1/2) inhibitor for the oral treatment of type 2 diabetes.